# People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

Study · id `cardio:ct-nct03520660` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03520660](<https://clinicaltrials.gov/study/NCT03520660>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03520660

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 121 participants.

## Technical summary

Registry record NCT03520660. Non-randomized; no masking; primary purpose treatment. Start 2018-10-19 (actual); primary completion 2032-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 121 participants (enrolled count; ClinicalTrials.gov record NCT03520660, source copy `cardio:ctgov-nct03520660-2026-10-22`, retrieved 2026-10-26)
- Started: 2018-10-19 (actual) (ClinicalTrials.gov record NCT03520660, source copy `cardio:ctgov-nct03520660-2026-10-22`, retrieved 2026-10-26)
- Primary completion: 2032-12-31 (anticipated) (ClinicalTrials.gov record NCT03520660, source copy `cardio:ctgov-nct03520660-2026-10-22`, retrieved 2026-10-26)
- Completion: 2032-12-31 (anticipated) (ClinicalTrials.gov record NCT03520660, source copy `cardio:ctgov-nct03520660-2026-10-22`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03520660, source copy `cardio:ctgov-nct03520660-2026-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03520660-2026-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
- Condition: Diabetes Mellitus
- Condition: Hepatitis C, Chronic
- Condition: Cardiovascular Diseases
- Intervention (Drug): Epclusa
- Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Lead sponsor class: NIH

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

## Provenance

Content hash: a190372947a70579787bea34d93ae7879889a699b4184c2ea2e544d2be2b9647
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
